Synthesis and biological evaluation of novel phenothiazine derivatives as non-peptide arginine vasopressin V2 receptor antagonists

被引:0
作者
Shuang Zhi [1 ]
Shuai Mu [1 ,2 ]
Ying Liu [2 ]
Min Gong [2 ]
Ping-Bao Wang [2 ]
Deng-Ke Liu [2 ]
机构
[1] School of Chemical Engineering and Technology,Tianjin University
[2] Tianjin Institute of Pharmaceutical Research
关键词
Arginine vasopressin V2 receptor; antagonist; Phenothiazine derivatives; Synthesis; Biological activities;
D O I
暂无
中图分类号
O626 [杂环化合物];
学科分类号
070303 ; 081704 ;
摘要
A series of novel phenothiazine derivatives was synthesized and tested for arginine vasopressin receptor antagonist activity.They were synthesized as novel arginine vasopressin receptor antagonists from phenothiazine as a scaffold via successive acylation,reduction and acylation reactions.Their structures were characterized by ~1H NMR,C NMR and HRMS,and biological activity was evaluated by in vitro and in vivo studies.The in vitro binding assay indicated that several compounds are potent selective V2 receptor antagonists.Compounds with promising binding affinity to V2 receptors were selected to conduct the in vivo diuretic studies on Sprague-Dawley rats.Among them.In,1r,1t and 1v exhibited excellent diuretic activity,especially 1 rand 1 v.Therefore,1r and 1v are potent novel AVPV2 receptor antagonist candidates.
引用
收藏
页码:627 / 630
页数:4
相关论文
共 12 条
  • [1] Synthesis and biological evaluation of novel derivatives of desloratadine.[J].Shuai Mu;Xiao-Shuai Xie;Duan Niu;Da-Shuai Zhang;Deng-Ke Liu;Chang-Xiao Liu;.Chinese Chemical Letters.2013, 06
  • [2] Lixivaptan – an evidence-based review of its clinical potential in the treatment of hyponatremia.[J].Mitchell Rosner;Bowman.Core Evidence.2013, defa
  • [3] Chronic activation of vasopressin V2 receptor signalling lowers renal medullary oxygen levels in rats
    Dietrich, A.
    Mathia, S.
    Kaminski, H.
    Mutig, K.
    Rosenberger, C.
    Mrowka, R.
    Bachmann, S.
    Paliege, A.
    [J]. ACTA PHYSIOLOGICA, 2013, 207 (04) : 721 - 731
  • [4] Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists.[J].Aimee L. Crombie;Thomas M. Antrilli;Brandon A. Campbell;David L. Crandall;Amedeo A. Failli;Yanan He;Jeffrey C. Kern;William J. Moore;Lisa M. Nogle;Eugene J. Trybulski.Bioorganic & Medicinal Chemistry Letters.2010, 12
  • [5] Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients.[J].JR Chiong;Geoffrey Jao;Savina Nodari.International Journal of Nephrology and Renovascular Disease.2010, defa
  • [6] Synthesis and structure–activity relationships of amide derivatives of (4;4-difluoro-1;2;3;4-tetrahydro-5 H -1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V 2 receptor agonists.[J].Issei Tsukamoto;Hiroyuki Koshio;Takahiro Kuramochi;Chikashi Saitoh;Hiroko Yanai-Inamura;Chika Kitada-Nozawa;Eisaku Yamamoto;Takeyuki Yatsu;Yoshiaki Shimada;Shuichi Sakamoto;Shin-ichi Tsukamoto.Bioorganic & Medicinal Chemistry.2009, 8
  • [7] AVP receptor antagonists in patients with CHF
    Kumar, Siva K.
    Mather, Paul J.
    [J]. HEART FAILURE REVIEWS, 2009, 14 (02) : 83 - 86
  • [8] Non-peptide arginine-vasopressin antagonists: the vaptans
    Decaux, Guy
    Soupart, Alain
    Vassart, Gilbert
    [J]. LANCET, 2008, 371 (9624) : 1624 - 1632
  • [9] Pyridobenzodiazepines: A novel class of orally active; vasopressin V 2 receptor selective agonists.[J].Amedeo A. Failli;Jay S. Shumsky;Robert J. Steffan;Thomas J. Caggiano;David K. Williams;Eugene J. Trybulski;Xiaoping Ning;Yeungwai Lock;Tarak Tanikella;David Hartmann;Peter S. Chan;C.H. Park.Bioorganic & Medicinal Chemistry Letters.2005, 4
  • [10] (4-Substituted-phenyl)-(5 H -10;11-dihydro-pyrrolo [2;1- c ][1;4] benzodiazepin-10-yl)-methanone derivatives as vasopressin receptor modulators.[J].Aranapakam M. Venkatesan;George T. Grosu;Amedeo A. Failli;Peter S. Chan;Joseph Coupet;Trina Saunders;Hussain Mazandarani;Xun Ru.Bioorganic & Medicinal Chemistry Letters.2005, 22